flutiform is an inhaled asthma treatment, containing a combination of the inhaled corticosteroid (ICS) fluticasone propionate and the long-acting beta-agonist (LABA) formoterol1.  It is administered through an aerosol inhaler, also known as a pressurised metered dose inhaler (pMDI). Usual dosage is two inhalations twice a day, that is two puffs (actuations) in the morning and two in the evening. 

flutiform is indicated for asthma maintenance therapy1, providing a rapid onset of bronchodilation2 and long lasting efficacy.3

  • 50µg/5µg inhaler is indicated in adults, adolescents and children aged 5 years and above.

  • flutiform 125µg/5µg inhaler is indicated in adults and adolescents aged 12 years and above.

  • flutiform 250µg/10µg inhaler is indicated in adults only.



  1.  flutiform Summary of Product Characteristics.  www.medicines.ie
  2. Aalbers R et al: Adv Ther 2012 Nov; 29(11):958-69
  3. Mansur A et al: JAMP 2013 Aug; 26(4): 190-9